The market value of these five Chinese medicine companies will rise by more than 50% by 2020.

"
Pharmaceutical Network Industry Dynamic" Since this year, affected by special reasons, some pharmaceutical stocks benefit in the short term, the performance increased significantlyAmong them, the Chinese medicine section performance is extremely strong, become a "bull stock concentration camp." Therefore, the author has collated the market value of 66 "Chinese medicine" listed enterprises since the beginning of the year, hoping to see from the market value changes which enterprises have more potential for developmentAnd after combing the author found that 26 Chinese medicine enterprises, market value has increasedAmong them, five pharmaceutical companies have increased their market value by more than 50%, and even some have reached nearly 130%the proportion of market value change of Yingling Pharmaceuticals: 129.21%data show that the recent high proportion of market value increase in Toling Pharmaceuticals, mainly benefited from the "Lianhua Qing pester products" in the outbreak played a major role and extensive marketing publicitybut during the comparison period as high as 245.84% of the market value ratio, in recent january to Ling Pharmaceuticals share price correction is obvious, market enthusiasm gradually cooled, is expected to come a long time, the capital market for the good news of The ridge Pharmaceuticals will form a certain degree of immunity, market value will also show a downward trendFor Ling Pharmaceuticals, the current and future more important task is how to face the time brought about by the sales of flat, how to let enterprises master more core competitivenessThe proportion of market value change of HuaHua Pharmaceuticals: 70.35%HuaHua Pharmaceutical is an older Chinese medicine enterprise in China, the core products are heart-slower tablets, bone dredging, Hodan tabletsThe production and sales of these three leading products directly determine the company's revenue and profitability, according to The PharmaceuticalsAccording to the 2019 semi-annual report, the revenue of the heart-to-heart film was RMB191 million, up 16.73% YoY, while the revenue of bone fracture scantise film was RMB101 million, up 30.45% YoY, and the revenue of Hodan Film was RMB45.37 million, up 214.11% YoYIn the case of a big increase in the sale of major products, this year, the market value of Huahua Pharmaceuticals can be imaginedthe proportion of Market Value change in Tibet Pharmaceutical industry: 129.21%The 2019 Annual Report of Tibet Pharmaceutical Industry showed that the company achieved revenue of 1.256 billion yuan, up 22.20% YoY, and achieved a net profit of 312 million yuan, up 44.86% YoYFor the reasons for the sharp rise in performance, the company said, mainly during the reporting period, the sales revenue of new live products increased by nearly 50% year-on-yearIt is reported that the new bio-type of new drugs, to a certain extent to fill the domestic treatment of acute heart failure gene engineering drugs, the drug can quickly improve heart failure patients heart failure symptoms and signs, and Tibet Pharmaceutical industry is the domestic exclusive production of new living hormone companiesthe proportion of market value change of Red Day Pharmaceuticals: 60.69%the current market value of Red Day Pharmaceuticals has four main factors, one is the company's Chinese medicine formula particle products continue to expand the market, continue to maintain the momentum of growth; Successfully included in the 2019 edition of the National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance Drug Catalog;in addition, the industry also believes that in May 2020, the State Drug Administration launched the listed chemical injections to carry out a consistent evaluation of generic drugs, Chinese medicine injections and even the entire field of Chinese medicine will see new hope, and red-day pharmaceutical industry's blood must be net injection will usher in more opportunitiesThe proportion of change in market value: 45.37%the tablet was listed in June 2003In recent years, its main revenue and net profit have maintained a rapid growth, even in the last two years of net profit has exceeded 40%According to the financial results, net profit increased by 22.88 percent year-on-year in 2019it is worth noting that the net cash flow from operating activities decreased by 243.62 percent year-on-year, with a serious divergence in profit and cash flow growth, and the growth rate of the company's performance has begun to show a downward trend since 2019In this regard, the industry believes that, as a well-known Chinese medicine enterprises, in front of the core of the problem should also be to do a good job of core product quality, at the same time in the decline in net profit growth, high deposit and loan, business transformation and so on.